|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2198b was selected from the S650/S654 region of human LLGL1/2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LLGL1 is a protein that is similar to a tumor suppressor in Drosophila. The protein is part of a cytoskeletal network and is associated with nonmuscle myosin II heavy chain and a kinase that specifically phosphorylates this protein at serine residues. The gene for LLGL1 is located within the Smith-Magenis syndrome region on chromosome 17. LLGL2 is a protein similar to lethal (2) giant larvae of Drosophila. In fly, the protein's ability to localize cell fate determinants is regulated by the atypical protein kinase C (aPKC). In human, this protein interacts with aPKC-containing complexes and is cortically localized in mitotic cells.
Schimanski, C.C., et al., Oncogene 24(19):3100-3109 (2005). Grifoni, D., et al., Oncogene 23(53):8688-8694 (2004). Katoh, M., et al., Int. J. Oncol. 24(3):737-742 (2004). Bi, W., et al., Genome Res. 12(5):713-728 (2002). Ludford-Menting, M.J., et al., J. Biol. Chem. 277(6):4477-4484 (2002). Yasumi, M., et al., J. Biol. Chem. 280(8):6761-6765 (2005).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.